UNASSIGNED: We studied nine pediatric cases with moderate to severe UC who after a median of 2.18 years of clinical remission on systemic immunotherapy stepped down to oral mesalamine treatment.
UNASSIGNED: Average follow-up time from SD was 3.49 years. Five patients (55.5%) had sustained remission (without any flare noted) after SD during follow-up. Sustained clinical remission was 88.9% (8/9) at 1 year, 87.5% (7/8) at 2 years, and 66.7% (4/6) at 3 years after SD. Out of those tested (one patient was not tested), 62.5% (5/8) had fecal calprotectin <50 μg/g. Four out of six patients examined (66.6%) had mucosal healing on post-SD colonoscopy.
UNASSIGNED: We propose that SD to mesalamine can be a reasonable therapeutic consideration for pediatric patients with UC before transitioning to adult gastroenterology care. Shared decision-making is important before such treatment changes.
我们研究了9例中度至重度UC的儿科病例,这些病例在接受全身免疫疗法的中位临床缓解时间为2.18年后,逐渐转向口服美沙拉嗪治疗。
■从SD开始的平均随访时间为3.49年。随访期间,5例患者(55.5%)在SD后持续缓解(无任何耀斑)。1年持续临床缓解率为88.9%(8/9),87.5%(7/8)在2年,SD后3年为66.7%(4/6)。在接受测试的患者中(一名患者未接受测试),62.5%(5/8)的粪便钙卫蛋白<50μg/g。在SD结肠镜检查后,接受检查的六名患者中有四名(66.6%)的粘膜愈合。
■我们建议,在过渡到成人胃肠病学治疗之前,SD对美沙拉嗪的治疗可以是小儿UC患者的合理治疗考虑。在这种治疗改变之前,共同的决策很重要。